HealthDay News – According to a research letter published online Aug. 11 in JAMA Oncology, the seropositivity rate in cancer patients remains high four months after the second dose of the COVID-19 vaccine.
Noa Eliakim-Raz, MD, of Rabin Medical Center in Petah Tikva, Israel, and colleagues studied the antispike (anti-S) immunoglobulin (Ig) G antibody response to the messenger RNA vaccine (BioNTech-Pfizer) in 95 cancer patients versus 66 controls about four months after the second dose of vaccine.
The researchers found that a median of 123 days after the second vaccination, 87 percent of the patients and 100 percent of the controls were seropositive for anti-S-IgG antibodies. In cancer patients, the mean titer values were significantly lower than in the control group (417 versus 1,220 arbitrary units per milliliter). The median IgG titers varied by 3.6-fold depending on the tumor type and 8.8-fold depending on the type of cancer treatment, the lowest titers being observed with immunotherapy plus chemotherapy and biological therapy.
“Long-term cellular memory could question the need for a third BNT162b2 booster dose,” the authors write.
One author revealed financial ties to the pharmaceutical industry.
Summary / full text (subscription or payment may be required)
Cancer COVID19 COVID19 Vaccines Oncology